Ind-Swift Laboratories Ltd — earnings calls

Ind-Swift Laboratories reported Q1 FY27 operating income of ₹186.08 crore, up 21.16% year-on-year, with operating EBITDA more than doubling to ₹33.32 crore and EBITDA margin expanding to 17.91%. Management said the export segment, particularly own-brand sales, grew to 57.20% of quarterly sales from 48% a year earlier, while newly commercialised CDMO partnerships with Viatris, Manx and Arrotex contributed modest revenue in the quarter. Management discussed capacity expansion, capital allocation of approximately ₹250 crore of cash over roughly two to two-and-a-half years, and provided updates on dossier filings, product registrations, and the Samba facility upgrade to EU-GMP and PIC/S standards.